BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that the company is advancing BCX9930, an oral Factor D inhibitor discovered and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE